Prognostic factors in stage II endometrial carcinoma

Area of Science:

• Gynecologic Oncology
• Radiation Oncology
• Surgical Pathology

Background:

• Stage II endometrial carcinoma is rare, complicating prognostic factor evaluation.
• Treatment modalities vary, further challenging prognostic assessments.
• Identifying reliable prognostic indicators is crucial for patient management.

Purpose of the Study:

• To evaluate clinical, surgical, and pathological prognostic factors in Stage II endometrial carcinoma.
• To identify significant predictors of survival in patients treated with pelvic irradiation and hysterectomy.
• To inform patient stratification for adjuvant therapy trials.

Main Methods:

• Retrospective analysis of 64 patients treated between 1965 and 1983.
• Evaluation of clinical characteristics, surgical findings (including lymph node status and cytology), and pathological features.
• Comparison of 5-year actuarial survival rates based on prognostic variables.

Main Results:

• Statistically significant prognostic factors included age, tumor grade, myometrial invasion depth, disease extent (lymph node metastases), and pelvic cytology.
• Race, weight, and cell type were not significant prognostic factors.
• Adverse prognostic factors identified patients for adjuvant therapy trials.

Conclusions:

• Age, grade, myometrial invasion, disease extent, and pelvic cytology are significant prognostic indicators for Stage II endometrial carcinoma.
• Surgical evaluation should include lymph node biopsies, omental biopsy, pelvic cytology, and suspicious tissue biopsy.
• Patients with adverse prognostic factors should be considered for clinical trials investigating adjuvant therapies.